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We explored the relationship between acute ischaemic stroke (IS) early functional outcome and serum levels of homocysteine,
vitamin B12, and D in a noninterventional prospective clinical study. We enrolled 50 patients with first-ever IS and performed
laboratory tests and functional assessment at three time points: on admission and three and six months after stroke. Modified
Rankin Scale (mRS), NIHSS scale, and Barthel index (BI) scores were assessed in all participants by trained examiner blinded to
laboratory data. Patients did not receive treatment thatmight alter laboratory data. AdmissionNIHSS correlatedwith homocysteine
levels (𝑟 = 0.304, 𝑝 < 0.05), B12 level (𝑟 = −0.410, 𝑝 < 0.01), and vitamin D levels (𝑟 = −0.465, 𝑝 < 0.01). Functional outcome
measures (BI and mRS) did not significantly correlate with homocysteine and vitamin D3 levels at 3 and 6 months. However,
a positive correlation with vitamin B12 levels was detected for BI both at 3 and 6 months and mRS at 6 months. Higher serum
vitamin B12 levels were associated with better functional outcome at follow-up.
1. Introduction
Stroke remains the third leading cause of death after heart
diseases and malignancies and the most frequent cause of
disability in people after 60 years of age worldwide, in spite of
extensive research and introduction of preventive measures
[1, 2]. Ischaemic stroke (IS) is mostly preventable and risk
factors are similar both in developed and in undeveloped
countries [3]. Treatable conditions comprise around 90%
of all risk factors, including arterial hypertension, diabetes
mellitus, cardiac diseases, cigarette smoking, obesity, hyper-
lipidemia, physical inactivity, alcohol overuse, unhealthy diet,
psychosocial stress, and depression [3, 4]. Although exten-
sive, this list is not complete and new potentially treatable
factors contributing to stroke risk are emerging continuously:
hyperhomocysteinemia, vitamin B12 and vitamin D defi-
ciencies, thyroid dysfunctions, and others [5]. There is also
evidence that adequate management of vascular risk factors
may be beneficial for functional outcome after stroke [5, 6].
Hyperhomocysteinemia increases the likelihood of stroke
and is mostly dependent on folic acid (vitamin B9), vitamin
B12, and vitamin B6 serum levels [7, 8]. Intestinal absorption
of many food constituents decreases with aging and is prob-
ably one of the factors influencing vitamin deficiencies and
hyperhomocysteinemia, although genetic polymorphisms
may also contribute to metabolic disturbances [9]. It has
been shown that homocysteine levels above 10.2 micromol/l
(mcmol/l) double the risk of stroke [10], while with homo-
cysteine levels above 20mcmol/l the risk is fourfold [11].
Supplementation with vitamins B9, B12, and B6 appears to
decrease the homocysteine levels and potentially contributes
to stroke prevention although direct evidence is lacking [12,
13].
Vitamin B12 deficiency can be detected in 10–40% of
the general population and may contribute to stroke and
cognitive decline [14, 15]. Serum B12 levels may not be
sufficientmeasures of B12 status but should be supportedwith
homocysteine and methyl malonic serum levels [15]. Also,
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cut-off scores of vitamin B12 blood levels can bemisleading as
there is a wide discrepancy among experts setting the normal
values in the range between 100 pmol/l and 350 pmol/l [16].
Vitamin B12 deficiency can be disclosed via elevated serum
homocysteine levels at first and only later with decreased
serum levels of vitamin B12; homocysteine levels should be
kept in the safe range with continuous supplementation,
bearing in mind that even B12 levels within the normal range
can be associatedwith an increased risk of stroke twofold [14].
Vitamin D deficiency has been associated with a proin-
flammatory state that induces blood vessels injury but is
also in relation to other vascular risk factors such as obesity,
insulin resistance, autoimmunity, dyslipidemia, and oxidative
stress [17–19]. Vitamin D deficiency has been related to an
increased risk for stroke [18, 20]. In a cohort study from
Hong Kong, in participants 45 years of age or older, a low
vitamin D level was associated with increased risk of IS. The
lowest risk was found at 25(OH)D levels between 70 and
80 nmol/l [21], while the optimal blood level is estimated to
range from 75 to 100 nmol/l (30 to 40 ng/ml) [22]. Vitamin
D status is influenced by at least another vascular risk factor,
smoking, showing that the interplay of various risk factors is
an important issue that should be addressed in stroke patients
[23].
Previous studies investigated mainly vitamins role in sec-
ondary stroke prevention rarely focusing on potential imp-
act on functional outcome after stroke, also eligible for an
early intervention [24]. Hyperhomocysteinemia higher than
10mcmol/l has been reported to be a risk factor for early
poststroke neurological deterioration after 7 days, probably
throughneurotoxicity and epithelium injury in the vessel wall
[25]. Low vitamin D status has also been suggested to be a
risk factor for worse stroke prognosis and poor functional
outcome [26]. Our study was designed to investigate the
relationship between IS and serum status of homocysteine,
vitamin B12, and vitamin D and go further to assess the
importance of these correctable factors during the functional
recovery three and six months after stroke, the time of the
most evident improvement in stroke survivors.
2. Methods
2.1. Participants. Our studywas a noninterventional prospec-
tive clinical study with 50 consecutive patients with acute
IS, admitted to regional hospital in Berane, Montenegro.
None of the patients were treated with rtTPA since it is not
available in our hospital. Patients were assessed at the baseline
and reassessed three and six months after stroke. Inclusion
criteria comprised first-ever IS, age between 18 and 90 years,
no previous injury to the central nervous system, and any
other acute or chronic incapacitating medical disease. Only
patients who survived the whole study period were included
in the final analysis. Scales assessing neurological deficit and
functional status and blood analyses were administered on
admission and after three and six months after acute IS.
Exclusion criteria for the study comprised previously known
vitamin D and B12 deficiency and/or hyperhomocysteinemia
or vitamin supplement therapy for other indications. Patients
were treated for stroke risk factors and secondary stroke
prevention as per current guidelines [27, 28]. Local Ethic
Committee approved the study.
2.2. Neuroimaging. Computerized tomography of the brain
was used to exclude hemorrhagic stroke and confirm diag-
nosis of IS.
2.3. Functional Measures. In our study, standard functional
measures were used:
(i) Modified Rankin Scale (mRS) [29, 30]
(ii) NIHSS scale [31, 32]
(iii) Barthel index (BI) [33].
Evaluation was performed by trained examiner who was
blinded to laboratory test results.
2.4. Blood Analysis. On all three visits morning fasting blood
was drawn for determination of homocysteine, vitamin B12,
and vitamin D levels.
2.5. Statistics. Along with descriptive statistics/measures,
data was analyzedwith independent samples 𝑡-test, Friedman
test, and Wilcoxon test (for post hoc comparison), as well as
Pearson correlation, using Statistical Package for the Social
Sciences (SPSS) for Windows Version 16.0.
Follow-up 3- and 6-month analyses with mRS and BI as
outcomes were adjusted for age and initial NIHSS.
3. Results
In our study group 22 (44%) participants were male and 28
(56%) female. Mean age was 71.96 ± 11.39, ranging between
45 and 90 years. Mean age was 72.79 ± 9.92 for females
and 70.86 ± 13.28 for males, with no significant differences
between sexes (𝑝 > 0.05). Clinical presentation comprised 25
(50%) cases with left-sided hemiparesis, 12 (24%) with right-
sided hemiparesis, 10 (20%) with left-sided hemiplegia, and 3
(6%) with right-sided hemiplegia. Scores on NIHSS, BI and
mRS are shown in Table 1. Admission NIHSS ranged from 5
to 22, mean 14±7. According to the score on NIHSS, patients
neurological deficit significantly improved over time of
follow-up, whichwas also reflected in BI andmRS scores, that
remained stable after 3-month follow-up visit.
Regarding laboratory data, homocysteine levels decrea-
sed and vitamin B12 andD levels increased during the follow-
up (Table 2). Mean values of all parameters were within the
pathological range.
Admission NIHSS correlated with homocysteine levels
(𝑟 = 0.304, 𝑝 < 0.05), B12 level (𝑟 = −0.410, 𝑝 < 0.01),
and vitamin D levels (𝑟 = −0.465, 𝑝 < 0.01).
After adjustment for age and baseline NIHSS, serum
homocysteine levels did not correlate with BI and mRS score
at 3- and 6-month follow-up visit. However, correlation with
BI at 6 months was at the level of statistical trend (𝑝 = 0.064)
(Table 3).
Vitamin B12 levels significantly positively correlated with
BI at 3 and 6 months and negatively with mRS levels at 6
months, after adjustment for age and NIHSS level. However,
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Table 1: NIHSS and functional scales (BI, mRS) at all time-points. Post hoc: Wilcoxon sign-rank test (Bonferroni correction).
Admission At 3 months At 6 months 𝑝 value
NIHSS 14 ± 7 12 ± 7 11 ± 7 <0.001 A, B, C
BI 72 ± 15 74 ± 16 75 ± 20 <0.001 A, B, C
mRS 4 ± 1 3 ± 1 3 ± 1 <0.001 A, B
NIHSS: National Institutes of Health Stroke Scale, BI: Barthel index, and mRS: Modified Rankin Scale.
0: admission versus at 3 months, B: admission versus at 6 months, and C: at 3 months versus at 6 months.
Table 2: Serumhomocysteine, vitaminB12, and vitaminD levels at all time-points. Post hoc:Wilcoxon sign-rank test (Bonferroni correction).
Admission At 3 months At 6 months 𝑝 value
Homocysteine 12.6 ± 3.7 11.6 ± 3.0 10.9 ± 3.0 <0,001 A, B, C
Vitamin B12 155.4 ± 70.9 179.6 ± 71.9 206.6 ± 79.0 <0,001 A, B, C
Vitamin D 30.2 ± 9.0 39.9 ± 12.9 52.2 ± 18.7 <0,001 A, B, C
0: admission versus at 3 months, B: admission versus at 6 months, and C: at 3 months versus at 6 months.
Table 3: Correlations of laboratory variables with BI and mRS corrected for age and initial NIHSS.
After 3 months After 6 months





Vitamin D BI .031 .193
mRS .049 −.231
Note. ∗𝑝 < 0.01. ∗∗𝑝 < 0.05.
correlation withmRS at 3months was at the level of statistical
trend (𝑝 = 0.064) (Table 3).
No correlationwas detected between vitaminD levels and
BI and mRS at both time points, after adjustment for age and
baseline stroke severity (Table 3).
4. Discussion
Results of study indicate significant association between ser-
um homocysteine, vitamin B12, and vitamin D status and IS
baseline severity. Also, a significant association was detected
between vitamin B12 levels and parameters of early functional
outcome after stroke. Since our patients did not receive any
intervention except for standard secondary stroke prevention
measures according to the current guidelines, we cannot
conclude that vitamin supplementation and homocysteine
reduction were associated with alteration of stroke outcome
[27, 28]. However, early intervention may be of most impor-
tance as functional improvement after IS was noted to be
most prominent in the first six months [34].
Homocysteine levels were decreasing in our IS patients
during the period of observation compared to baseline levels.
Our patients were not treated during the period of the
study with vitamin supplementation that has been shown to
reduce homocysteinemia and whether this is the result of
diet changes is difficult to assess [13, 35]. Study of Wu and
coworkers (2014) [36] showed that hyperhomocysteinemia in
the first 72 hours after IS has negative prognostic impact on
functional outcome after 6, 12, and 18 months, according to
the scores on NIHSS, mRS, and BI. In this study elevated
homocysteine levels were defined as >15 𝜇mol/l [36]. In
our study hyperhomocysteinemia only correlated with worse
functional outcomemeasuredwithBI at 6months after stroke
but at the level of statistical trend. Results of the Cilostazol
in Acute Ischaemic Stroke Treatment (CAIST) study found
homocysteinemia to be significant risk for early worsening
of neurological status in first seven days after stroke [25]. In
study by Mizrahi et al. (2005), no correlation between homo-
cysteine level and functional outcome was detected when the
Functional Independence Measure (FIM) tool was used [37],
which could reflect the problem of different study designs
and methodology for functional status assessment between
different studies. Data on longer poststroke follow-up period
are available from the study by Lee and coauthors showed that
18months after IS patients with high homocysteine levels had
significantly lower BI and higherNIHSS andmRS scores [35].
Interestingly, higher homocysteine group also had higher
rate of reinfarction than the lower homocysteine group [36].
The fatigue scale score correlated with higher homocysteine
serum level and lower BI as well [38].
In the study of Youssef and coworkers [39] homocys-
teine and C-reactive protein (CRP) levels significantly corre-
lated with prognosis of cerebrovascular disease according to
NIHSS and mRS scores. Similar results were obtained in the
study of Tu and coauthors, who found that a high-sensitivity
CRP and homocysteine were independent predictors of
short-term outcome and mortality after IS, adjusted for age
and NIHSS score [40]. In a retrospective study, Men and
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coworkers [41] reported an independent predictive value of
elevated homocysteine and CRP after IS with unfavorable
outcome after a month. Our analysis adjusted for age and
baseline stroke severity showed that 6months after a stroke BI
scores negatively correlated with homocysteine levels at the
level of statistical trend, with higher BI scores associated with
lower homocysteine levels.
In the substudy of the Heart Outcomes Prevention Eva-
luation 2 (HOPE 2) study, a significant reduction of homocys-
teine levels due to supplementation with 2.5mg of folic acid,
50mg of vitamin B6, and 1mg of vitamin B12 every day dur-
ing five years led to significant lowering of stroke incidence
in patients with cardiovascular risk factors [42]. Although
reduced risk of nonfatal stroke was noted, homocysteine
lowering did not influence the outcome 7 days after stroke
according to the mRS score [42]. A meta-analysis published
in 2010 confirmed effects of vitamin B supplementation on
lowering the serum homocysteine levels but did not demon-
strate a major effect in averting stroke [35, 43].
Most of the studies indicated that the risk of stroke
diminishes significantly only with homocysteine levels lower
than 10mcmol/L [44–46]. Also, all-cause mortality from
elevated homocysteine significantly decreased only when
levels are less than 9mcmol/L [46]. According to other data,
atherosclerotic riskwas elevated if serumhomocysteine levels
were ≥6.3 𝜇mol/L [47]. Additional data are available from the
study by Hodis and coworkers, reporting that longstanding
supplementation with high doses of B vitamins slows the
progression of subclinical carotid atherosclerosis in people
with homocysteine levels above 9mcmol/L [48].
Intriguing finding is that vitamin B12 and D serum levels
increased during the period of follow-up in our cohort, and
no supplementation was offered to the patients.This could be
secondary to dietary changes but our study was not designed
to assess this.
An important correlationwas found between vitamin B12
levels and functional status at all time points after stroke. A
discrepancy between extracellular markers and intracellular
biochemical reactions of vitamin B12 has been noted, with
serum levels being significantly higher than cellular levels
[49]. Consequently, apparently normal vitamin B12 serum
level can be found in patients with vitamin B12 deficiency.The
earliest marker of deficiency is low holotranscobalamin level
followed by dysfunction of intracellular enzymes, followed
by elevation of methylmalonic acid and homocysteine levels
[49, 50]. In our group higher vitamin B12 levels correlated
significantly with higher BI and lower mRS indicating better
functional status, and the relationship remained significant 3
and 6months after stroke.These findings disclose importance
of vitamin B12 screening in stroke population.
There is some evidence that vitamin D deficiency is
associated with an increased risk for vascular diseases and
it also increases general mortality [19, 51]. In the study by
Park and coworkers [19] only minority (13.6%) of patients
had optimal vitamin D levels of ≥75 nmol/l at the time of
stroke. A recent French study [52] also showed that vitaminD
deficiency is very frequent in IS patients. On admission, our
patients exhibited statistically significant correlation between
vitaminDandNIHSS scores, indicating less deficit in patients
with higher vitamin D serum levels. Supporting this is a
finding from study by Turetsky and authors who detected
by neuroimaging study of infarct volume that low vitamin D
levels at the time of admission correlatedwithmore tissue loss
[53].
Mean baseline vitamin D levels remained decreased in
our IS cohort. We failed to detect any correlation between
vitamin D levels and functional outcome after stroke when
analysis was adjusted for age and baseline NIHSS. Some
researchers reported better outcome measured with BI in
patients with higher vitamin D serum levels after three
months [19]. Interestingly, an increased mortality one year
after stroke in patientswith lowvitaminD levels on admission
was registered, particularly in patients younger than 75 years
of age [53].
There are some limitations of our study. Study group com-
prised small number of participants and therefore results
should be interpreted with caution.This is a longitudinal reg-
istry of closely followed up patients with no missing data but
with no control group involved. Since only surviving patients
were included in the final analysis, we did not account for the
competing mortality. We performed adjustment for age and
baseline NIHSS data, but the 𝑝 values were not adjusted for
multiple testing.
5. Conclusion
Our findings indicate that serum homocysteine, vitamin B12,
and vitamin D levels are associated with baseline first-ever
stroke severity but also contribute to some extent to IS
prognosis in early period after stroke.There is some evidence
that early detection and management of these laboratory
parameters may contribute both to primary and to secondary
stroke prevention but whether interventions aimed at reduc-
ing homocysteine levels and increasing vitamin B12 and D
levels would improve IS outcome remains to be elucidated in
larger multicenter intervention studies.
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